0 19 N-acetyl-L-cysteine N-acetyl-L-cysteine NNP 20 28 inhibits inhibit VBZ 29 36 primary primary JJ 37 42 human human JJ 43 44 T t NN 45 49 cell cell NN 50 59 responses response NNS 60 62 at at IN 63 66 the the DT 67 76 dendritic dendritic JJ 77 81 cell cell NN 82 87 level level NN 87 88 : : : 89 100 association association NN 101 105 with with IN 106 115 NF-kappaB NF-kappaB NNP 116 126 inhibition inhibition NN 126 127 . . . 129 148 N-acetyl-L-cysteine N-acetyl-L-cysteine NNP 149 150 ( ( ( 150 153 NAC NAC NNP 153 154 ) ) ) 155 157 is be VBZ 158 160 an an DT 161 172 antioxidant antioxidant JJ 173 181 molecule molecule NN 182 189 endowed endow VBN 190 194 with with IN 195 211 immunomodulatory immunomodulatory JJ 212 222 properties property NNS 222 223 . . . 224 226 To to TO 227 238 investigate investigate VB 239 242 the the DT 243 249 effect effect NN 250 252 of of IN 253 256 NAC NAC NNP 257 259 on on IN 260 263 the the DT 264 273 induction induction NN 274 279 phase phase NN 280 282 of of IN 283 284 T t NN 285 289 cell cell NN 290 299 responses response NNS 299 300 , , , 301 303 we we PRP 304 312 analyzed analyze VBD 313 316 its its PRP$ 317 323 action action NN 324 326 on on IN 327 332 human human JJ 333 342 dendritic dendritic JJ 343 348 cells cell NNS 349 350 ( ( ( 350 352 DC DC NNP 352 353 ) ) ) 354 361 derived derive VBN 362 366 from from IN 367 375 adherent adherent JJ 376 380 PBMC PBMC NNP 381 389 cultured culture VBN 390 394 with with IN 395 399 IL-4 il-4 NN 400 403 and and CC 404 426 granulocyte-macrophage granulocyte-macrophage JJ 427 430 CSF CSF NNP 430 431 . . . 432 434 We we PRP 435 440 first first RB 441 446 found find VBD 447 451 that that IN 452 455 NAC NAC NNP 456 465 inhibited inhibit VBD 466 469 the the DT 470 482 constitutive constitutive JJ 483 485 as as RB 486 490 well well RB 491 493 as as IN 494 497 the the DT 498 509 LPS-induced lps-induced JJ 510 518 activity activity NN 519 521 of of IN 522 525 the the DT 526 539 transcription transcription NN 540 546 factor factor NN 547 556 NF-kappaB nf-kappab NN 556 557 . . . 558 560 In in IN 561 569 parallel parallel NN 569 570 , , , 571 574 NAC NAC NNP 575 578 was be VBD 579 584 shown show VBN 585 587 to to TO 588 601 down-regulate down-regulate VB 602 605 the the DT 606 616 production production NN 617 619 of of IN 620 629 cytokines cytokine NNS 630 632 by by IN 633 635 DC DC NNP 636 638 as as RB 639 643 well well RB 644 646 as as IN 647 652 their their PRP$ 653 660 surface surface NN 661 671 expression expression NN 672 674 of of IN 675 681 HLA-DR HLA-DR NNP 681 682 , , , 683 687 CD86 CD86 NNP 688 689 ( ( ( 689 693 B7-2 B7-2 NNP 693 694 ) ) ) 694 695 , , , 696 699 and and CC 700 704 CD40 cd40 NN 705 714 molecules molecule NNS 715 719 both both CC 720 722 at at IN 723 726 the the DT 727 732 basal basal JJ 733 738 state state NN 739 742 and and CC 743 747 upon upon IN 748 751 LPS LPS NNP 752 762 activation activation NN 762 763 . . . 764 767 NAC NAC NNP 768 772 also also RB 773 782 inhibited inhibit VBD 783 785 DC DC NNP 786 795 responses response NNS 796 803 induced induce VBN 804 806 by by IN 807 811 CD40 cd40 NN 812 822 engagement engagement NN 822 823 . . . 824 827 The the DT 828 838 inhibitory inhibitory JJ 839 846 effects effect NNS 847 849 of of IN 850 853 NAC NAC NNP 854 858 were be VBD 859 862 not not RB 863 866 due due JJ 867 869 to to TO 870 881 nonspecific nonspecific JJ 882 890 toxicity toxicity NN 891 893 as as IN 894 901 neither neither CC 902 905 the the DT 906 915 viability viability NN 916 918 of of IN 919 921 DC DC NNP 922 925 nor nor CC 926 931 their their PRP$ 932 939 mannose mannose NN 940 957 receptor-mediated receptor-mediated JJ 958 969 endocytosis endocytosis NN 970 974 were be VBD 975 983 modified modify VBN 984 986 by by IN 987 990 NAC NAC NNP 990 991 . . . 992 999 Finally finally RB 999 1000 , , , 1001 1003 we we PRP 1004 1009 found find VBD 1010 1014 that that IN 1015 1018 the the DT 1019 1027 addition addition NN 1028 1030 of of IN 1031 1034 NAC NAC NNP 1035 1037 to to TO 1038 1041 MLR MLR NNP 1042 1049 between between IN 1050 1055 naive naive JJ 1056 1057 T t NN 1058 1063 cells cell NNS 1064 1067 and and CC 1068 1078 allogeneic allogeneic JJ 1079 1081 DC DC NNP 1082 1090 resulted result VBD 1091 1093 in in IN 1094 1095 a a DT 1096 1104 profound profound JJ 1105 1115 inhibition inhibition NN 1116 1118 of of IN 1119 1131 alloreactive alloreactive JJ 1132 1141 responses response NNS 1141 1142 , , , 1143 1148 which which WDT 1149 1154 could could MD 1155 1157 be be VB 1158 1168 attributed attribute VBN 1169 1171 to to TO 1172 1173 a a DT 1174 1180 defect defect NN 1181 1183 of of IN 1184 1186 DC DC NNP 1187 1189 as as IN 1190 1205 APC-independent apc-independent JJ 1206 1207 T t NN 1208 1212 cell cell NN 1213 1222 responses response NNS 1223 1227 were be VBD 1228 1231 not not RB 1232 1241 inhibited inhibit VBN 1242 1244 by by IN 1245 1248 NAC NAC NNP 1248 1249 . . . 1250 1260 Altogether altogether RB 1260 1261 , , , 1262 1265 our our PRP$ 1266 1273 results result NNS 1274 1281 suggest suggest VBP 1282 1286 that that IN 1287 1290 NAC NAC NNP 1291 1296 might might MD 1297 1303 impair impair VB 1304 1307 the the DT 1308 1318 generation generation NN 1319 1321 of of IN 1322 1329 primary primary JJ 1330 1336 immune immune JJ 1337 1346 responses response NNS 1347 1349 in in IN 1350 1356 humans human NNS 1357 1364 through through IN 1365 1368 its its PRP$ 1369 1379 inhibitory inhibitory JJ 1380 1386 action action NN 1387 1389 on on IN 1390 1392 DC DC NNP 1392 1393 . . .